44 results on '"Waldstreicher, Joanne"'
Search Results
2. A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC)
3. Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.
4. Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation
5. Data Sharing -- A New Era for Research Funded by the U.S. Government.
6. Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies
7. Sustained Decrease in Incidence of Acute Urinary Retention and Surgery With Finasteride for 6 Years in Men With Benign Prostatic Hyperplasia
8. A systemic type I 5 α-reductase inhibitor is ineffective in the treatment of acne vulgaris
9. Lowering Low Density Lipoprotein Cholesterol with Simvastatin, a Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Does Not Affect Luteal Function in Premenopausal Women
10. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia
11. Measuring Reversal of Hair Miniaturization in Androgenetic Alopecia by Follicular Counts in Horizontal Sections of Serial Scalp Biopsies: Results of Finasteride 1 mg Treatment of Men and Postmenopausal Women
12. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
13. The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial
14. THE LONG-TERM EFFECTS OF FINASTERIDE ON BPH: RESULTS OF A FOUR-YEAR, PLACEBO-CONTROLLED STUDY
15. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia
16. Androgen antagonists: Potential role in prostate cancer prevention
17. How Johnson & Johnson Made Hard Decisions During Covid.
18. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride
19. SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
20. Finasteride in the treatment of men with frontal male pattern hair loss
21. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo
22. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia
23. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?
24. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
25. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia
26. Bumps and bridges on the road to responsible sharing of clinical trial data.
27. The Yale Open Data Access (YODA) Project--A Mechanism for Data Sharing.
28. Patient-Perceived Importance of Negative Effects of Androgenetic Alopecia in Women.
29. Managing Conflicts of Interest in Industry-Sponsored Clinical Research: More Physician Engagement Is Required.
30. Data Acquisition, Curation, and Use for a Continuously Learning Health System.
31. Lowering LDL cholesterol with simvastatin, an HMG-CoA reductase inhibitor, does not affect luteal function in women
32. A multirater validation study to assess the reliability of acne lesion counting
33. Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride
34. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride
35. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia
36. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia
37. Storage (Irritative) and Voiding (Obstructive) Symptoms as Predictors of Benign Prostatic Hyperplasia Progression and Related Outcomes
38. Reply
39. Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing.
40. Overview and experience of the YODA Project with clinical trial data sharing after 5 years.
41. Compassionate Use: A Modest Proposal.
42. Globalized pediatric research.
43. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris.
44. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.